['rheumatoid arthritis']
['filgotinib', 'placebo to match filgotinib', 'adalimumab', 'placebo to match adalimumab', 'mtx']

        Key Inclusion Criteria:

          -  Have a diagnosis of rheumatoid arthritis (RA) [2010 American College of Rheumatology
             (ACR)/European League Against Rheumatism (EULAR) criteria] , and are ACR functional
             class I-III.

          -  Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥
             6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both
             screening and Day 1.

          -  Ongoing treatment with a stable dose of MTX

        Key Exclusion Criteria:

          -  Previous treatment with any janus kinase (JAK) inhibitor

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      